文献速递银屑病与炎症性皮肤病

银屑病患者司库奇尤单抗群体药代动力学-药效学模型

Population pharmacokinetic-pharmacodynamic model for secukinumab in patients with psoriasis.
PubMed 文献 · J Invest Dermatol · 2026-07-08

本研究基于BeNeBio和BIOLOPTIM研究中61例成人银屑病患者的244次血清浓度和262次PASI评分,建立司库奇尤单抗联合群体药代动力学-药效学模型。模型采用一室模型(一级吸收和消除,清除率和分布容积异速缩放)及间接反应最大药物效应转换模型描述PASI应答。模拟确定第24周谷浓度目标14.5 μg/ml和35.5 μg/ml,分别与90%概率达到PASI≤2和PASI≤1相关,为模型引导精准给药提供基础。

要点

  • 司库奇尤单抗药代动力学符合一室模型,清除率和分布容积采用异速缩放。
  • 第24周谷浓度14.5 μg/ml对应90%概率PASI≤2,35.5 μg/ml对应90%概率PASI≤1。
  • 该模型为银屑病生物制剂模型引导精准给药的未来评估提供基础。

核心结论

  • 司库奇尤单抗在真实世界银屑病患者中的暴露-反应关系得到表征,并提供了临床合理的浓度目标。

研究设计与样本

  • 基于BeNeBio(NCT04340076)和BIOLOPTIM(NCT04080661)研究,纳入61例成人银屑病患者,共244次血清浓度测量和262次PASI评分。
  • 建立联合群体药代动力学-药效学模型,药代动力学为一室模型(一级吸收和消除,清除率和分布容积异速缩放),药效学为间接反应最大药物效应转换模型。

主要发现

  • 模拟确定第24周谷浓度目标14.5 μg/ml与90%概率达到PASI≤2相关。
  • 模拟确定第24周谷浓度目标35.5 μg/ml与90%概率达到PASI≤1相关。

关键数值与推荐

  • 第24周谷浓度14.5 μg/ml:90%概率PASI≤2。
  • 第24周谷浓度35.5 μg/ml:90%概率PASI≤1。

临床怎么用

  • 该模型可为未来银屑病生物制剂模型引导精准给药的评估提供基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psoriasis is a chronic immune-mediated inflammatory disease for which biologic therapies have substantially improved clinical outcomes; however, long-term treatment costs and potential safety concerns highlight the need for dose optimization. Model-informed precision dosing may support individualized biologic use but requires reliable pharmacokinetic/pharmacodynamic models based on patient-level data. This study aimed to characterize the pharmacokinetic/pharmacodynamic relationship of secukinumab in a real-world adult psoriasis population to support the future implementation of model-informed precision dosing. A joint population pharmacokinetic/pharmacodynamic model was developed using 244 serum concentration measurements and 262 PASI scores from 61 patients from the BeNeBio (NCT04340076) and BIOLOPTIM (NCT04080661) studies. Secukinumab pharmacokinetics were best described by a 1-compartment model with first-order absorption and elimination, with allometric scaling on clearance and volume of distribution. The PASI response was characterized using an indirect response maximal drug effect turnover model. Simulations identified week 24 trough concentration targets of 14.5 μg/ml and 35.5 μg/ml, which were associated with a 90% probability of achieving PASI ≤ 2 and PASI ≤ 1, respectively. These results characterize secukinumab exposure-response relationships in a real-world setting and provide clinically plausible concentration targets. The model provides a foundation for the future evaluation of model-informed precision dosing in biologic dosing for psoriasis.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Eylenbosch A, Soenen R, van Riel CA, et al. Population pharmacokinetic-pharmacodynamic model for secukinumab in patients with psoriasis. J Invest Dermatol. 2026. PMID: 42419628. doi:10.1016/j.jid.2026.06.1285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。